ZNF217 and uterine cancer: This strategy holds potential for broader application across various cancers, including brain, breast, colon, gastric, liver, ovarian, pancreatic, and uterine cancers, in which ZNF217 has been reported to be amplified and correlates with a worse prognosis 22-33.